Loring Wolcott & Coolidge Fiduciary Advisors 13F: Cuts REGN Stake by $20M

Loring Wolcott & Coolidge Fiduciary Advisors cut its position in Regeneron Pharmaceuticals, Inc. (REGN) by 26,114 shares in a filing on October 23, 2026.

REGN Regeneron Pharmaceuticals, Inc.

$805.02 ▲ +4.10% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Where Regeneron Fits in Loring Wolcott's Portfolio

This stake now accounts for about 0.4% of Loring Wolcott's reported 13F portfolio. The cut represents a 39.6% decrease in their position, indicating a significant shift in their investment strategy regarding Regeneron.

Other Institutional Activity in Regeneron

Evergreen Capital Management reduced its holdings by 3,547 shares, leaving it with 14,214 shares valued at about $10.8 million. SteelPeak Wealth also trimmed its position by 21,939 shares, exiting entirely from Regeneron. Dodge & Cox held 4,458,238 shares, with a slight decrease of 138,120 shares, valued at about $2.7 billion.

Regeneron Pharmaceuticals, Inc. Stock Down 1.7%

Regeneron shares recently traded at about $805.02, which is roughly equal to the price on the day of the filing. The stock is currently above its 50-day moving average by about 1.7% and above its 200-day moving average by about 9.4%. However, it is about 6.3% below its 52-week high of $859.34.

Recent Earnings

In the trailing twelve months, Regeneron reported revenue of approximately $15.5 billion and an EPS of $40.44. Investors can look forward to the next earnings report scheduled for October 30, 2026.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Several insiders sold shares recently, including Director Kathryn Ph.D. Guarini, who sold 400 shares at $800 each on August 10, 2026, and Officer Marion E Mccourt, who sold 2,346 shares on September 3, 2026. These transactions suggest active management among insiders.

Analysts Set New Price Targets

On October 15, 2026, UBS upgraded its rating to Buy with a target price of $978, up from $660. Piper Sandler maintained an Overweight rating with a target of $865 on October 19, 2026. The consensus rating for Regeneron is a Buy, with a mean price target of $867.33 based on 27 analyst opinions.

About Regeneron

Regeneron Pharmaceuticals, Inc. discovers and develops medicines for various diseases, including eye and neurological conditions, cancer, and rare diseases. Its recent position changes by institutional investors highlight ongoing interest and adjustments in this biotech firm.

Bottom Line

Investors should keep an eye on Regeneron's performance as the next earnings date approaches on October 30, 2026. The latest 13F filing from Loring Wolcott reflects significant changes in their investment strategy regarding this stock.